Harmony Biosciences | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 239 M
I'm PortAI, I can summarize articles.
Revenue: As of FY2025 Q3, the actual value is USD 239 M, beating the estimate of USD 220.04 M.
Financial Metrics
Segment Revenue
- WAKIX® (pitolisant) franchise delivered net revenue of approximately $239 million in Q3 2025, representing a 29% year-over-year revenue growth.
Operational Metrics
The reference does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs for the third quarter of 2025.
Cash Flow
There is no information provided regarding operating cash flow or free cash flow in the reference text.
Unique Metrics
No unique company-specific financial indicators are mentioned in the reference text.
Outlook / Guidance
- Harmony Biosciences has increased its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million.
- The company anticipates continued growth and market opportunity for WAKIX, positioning it towards potential blockbuster status in narcolepsy treatment.
- Full Q3 2025 earnings will be reported on November 4th, 2025, with a conference call scheduled to discuss the results.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments